Management of hemangiomas by propranolol: Epidemiological, clinical and therapeutic aspects: retrospective study about 15 cases

• Published in: Nasza dermatologia online 2018-02, Vol.9 (1), p.7-10
• Main Authors: Doulla, Moussa, Bako, Harouna, Salissou, Laouali, Ouédraogo, Maimouna M, Hassane, Ide, Abdoulaye, Mariama, Moumouni, Hassan
• Format: Article
• Language: English
• Subjects: Age; Angioma; Hemangioma; Propranolol; Epidemiology; Hemangioma; Lasers; Software
• ISSN: 2081-9390; 2081-9390
• DOI: 10.7241/ourd.20181.2

The objective of this study was to determine the epidemiological, clinical and therapeutic profile of cutaneous hemangioma at the Niamey National Hospital. This is a retrospective study carried out over a period of 2 years, in the Unity of Dermatology and Venerology. Out of a total of 1648 consultations in 2 years, 33 cases of cutaneous angioma were identified; which represented 2%. The prevalence was predominantly female (80%) and the sex ratio M/F was 0.25. The age group 0-5 months was more represented (66.7%) with ages ranging 2 days and 24 months. Of the 33 cases of angioma, 25 were hemangiomas and 8 were malformations without any cardiac anomalie. Patients retained for the study were those with hemangioma (25 cases with 76%) who received the Propranolol protocol used in the oral dosage of 1 mg/kg/day for 24 months. Only 15 patients recovered totally from hemangioma. Tolerance was good in 93.3%. Conclusion: Several therapies still show their limit. Due to the often serious side effects with corticosteroids, treatment based on betablockers can be a way of the future, given the satisfaction of results and the good tolerance to these molecules.